<DOC>
	<DOCNO>NCT00715975</DOCNO>
	<brief_summary>The Psoriasis chronic dermatosis characterize abnormal proliferation cell epithelial , vessel dilation inflammation locally , present erythematous-scaly lesion various area body , preferably scalp , region religious joint elbow knee . It occur equally sexes appear age , mean age onset disease around 27.3 year . The halobetasol propionate ultra-potent corticoid . Its chemical structure similar Clobetasol corticoid , classify potent corticoid use worldwide clinical practice . However , molecular structure Halobetasol give increase activity antiinflammatory anti-proliferative . The objective study evaluate efficacy tolerability drug Halobetasol propionate cream formulation treatment patient plaque psoriasis mild moderate , compare substance similar power , Clobetasol propionate - Psorex - Cream .</brief_summary>
	<brief_title>Effectiveness Safety Topical Halobetasol Propionate Treatment Patients With Psoriasis</brief_title>
	<detailed_description>The patient eligible informed procedure study agree participate sign TCLE initially evaluate clinically clinical diagnosis psoriasis plate mild moderate involvement 20 % body surface . After procedure selection ( initial clinical evaluation verification criterion inclusion exclusion ) patient photograph , receive treatment target manage proper way standardize , home . In return ( 7 , 14 day ) hold photographs injury , clinical examination , evaluation adverse event dispense medicine patient . The drug dispense sufficient daily use next return . The product apply day , night , preferably bath . The follow-up visit occur time 07 14 day start treatment . If complete improves disease , treatment interrupted date . On visit examine clinical parameter validate scale assessment internationally ( PASI ) , provide exact data change framework patient parameter measure . As parameter tolerability evaluate frequency intensity adverse event potential irritative formulation , hold photo patient questionnaires cosmeticidade formulation . Patients gear expose sun treatment period . At end study , patient present evolution full injury release study still obvious symptom treatment interrupt risk prolong use drug study . These patient refer Health Service maintenance treatment new therapy . The patient release make recurrence disease due rebound effect</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Halobetasol</mesh_term>
	<criteria>Patients sex , adult 18 year , holder psoriasis plat mild moderate , Patients area involvement 20 % body surface , Patients good physical mental health Patients agree purpose study sign Informed Consent Patients skin diseases psoriasis alter clinical evaluation development disease , Patients psoriasis 20 % body , Patients type psoriasis `` plating '' , patient scalp psoriasis difficulty application product , Patients make topical treatment psoriasis 2 month precede study , Patients make systemic treatment psoriasis 4 month precede study , Patients agree condition describe Statement Informed Consent Patients pregnant breastfeeding , Patients use oral anticoagulant , Patients psoriatics addition plaque skin disorder cause fungi bacteria .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>clobetasol</keyword>
	<keyword>halobetasol</keyword>
	<keyword>psoriasis</keyword>
	<keyword>evaluate efficacy tolerability drug Halobetasol propionate</keyword>
</DOC>